206P Avatrombopag for the treatment of immune checkpoint inhibitor/targeted therapy-related thrombocytopenia in patients with hepatocellular carcinoma: A prospective, multicenter, single-arm trial

weight !60kg, po, qd) and hepatic arterial infusion tislelizumab (200mg, q3w) and mFOLFOX chemotherapy.The primary endpoint is ORR per RECIST v1.1.Results: From May 2022 to Nov 2023, 20 pts were enrolled: median age 60.5 (range, 31-79), 85% male, 70% ECOG PS score of 1, 85% Child-Pugh class A, 55% BCLC stage C, 55% hepatitis B infection, 40% with AFP > 400ng/ml.All pts received at least 1 dose of tislelizumab.At the data cut-off (Jun 14 th ,2024), the ORR was 50% (n10) per RECIST v1.1 and 65% (n13) per mRECIST.The DCR was 95% (n19) per RECIST v1.1 or mRECIST.Median PFS and OS were not reached.Treatment related AEs of any grade occurred in 100% patients.The most common TRAEs (incidence !10%) included asthenia (100%) and liver dysfunction (10%).Only 1 (5%) pt reported Grade 3-4 TRAEs (AST/ALT elevated and hypoalbuminemia).Conclusions: In this study, hepatic arterial infusion tislelizumab and chemotherapy plus DEB-TACE in combination with Lenvatinib showed potential efficacy and acceptable safety for first line treatment of unresectable HCC.